Solid Biosciences Inc.
For the period ended Dec 31, 2025. Filed Mar 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 19, 2026
SLDB$7.17+2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at December 31, 2025 and 2024
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $59,900 | $80,235 |
| Available-for-sale securities | 127,950 | 68,685 |
| Prepaid expenses and other current assets | 16,384 | 8,382 |
| Restricted cash, current | 1,222 | — |
| Total current assets | 205,456 | 157,302 |
| Non-current assets: | ||
| Operating lease, right-of-use assets | 21,924 | 24,295 |
| Property and equipment, net | 4,169 | 4,747 |
| Other non-current assets | 223 | 366 |
| Restricted cash, net of current portion | 768 | 1,952 |
| Total non-current assets | 27,084 | 31,360 |
| Total assets | $232,540 | $188,662 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $3,224 | $4,237 |
| Accrued expenses and other current liabilities | 18,945 | 19,852 |
| Operating lease liabilities, current | 2,103 | 1,787 |
| Finance lease liabilities | — | 1,231 |
| Derivative liabilities | 9,200 | 3,150 |
| Total current liabilities | 33,472 | 30,257 |
| Non-current liabilities: | ||
| Operating lease liabilities, net of current portion | 19,058 | 21,159 |
| Total non-current liabilities | 19,058 | 21,159 |
| Total liabilities | 52,530 | 51,416 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2025 and 2024; no shares issued and outstanding at December 31, 2025 and 2024 | — | — |
| Common stock, $0.001 par value; 240,000,000 and 120,000,000 shares authorized at December 31, 2025 and 2024, respectively; 78,967,888 and 40,468,141 shares issued and outstanding at December 31, 2025 and 2024, respectively | 79 | 40 |
| Additional paid-in capital | 1,137,654 | 920,609 |
| Accumulated other comprehensive income | 52 | 47 |
| Accumulated deficit | (957,775) | (783,450) |
| Total stockholders’ equity | 180,010 | 137,246 |
| Total liabilities and stockholders’ equity | $232,540 | $188,662 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.